Literature DB >> 18305053

Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.

Li Ning1, David Yu Greenblatt, Muthusamy Kunnimalaiyaan, Herbert Chen.   

Abstract

Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) malignancy that frequently metastasizes and has limited treatments. We recently reported that ectopic expression of Notch-1 in human MTC cells suppresses growth. The objective of this study was to evaluate the ability of suberoyl bis-hydroxamic acid (SBHA) to modulate Notch-1 signaling in MTC cells. At baseline, no active Notch-1 protein was present in MTC cells. Treatment with SBHA resulted in a dose-dependent induction of the Notch-1 intracellular domain, the active form of the protein. Furthermore, with Notch-1 activation there was a concomitant decrease in achaete-scute complex-like 1 (ASCL-1), a downstream target of Notch-1 signaling, as well as the NE tumor marker chromogranin A (CgA). Transfection of Notch-1 small-interfering RNA into MTC cells blocked the effects of SBHA on Notch-1 activation, ASCL-1, and CgA. Importantly, SBHA treatment resulted in a dose-dependent decrease in cell viability. Treated cells had an increase in protein levels of cleaved caspase-3 and poly ADP-ribose polymerase, and changes in the expression of apoptotic mediators including Bcl-X(L) and Bad, indicating that the growth inhibition was a result of apoptosis. These results demonstrate that SBHA activates Notch-1 signaling, which is associated with the antiproliferative and apoptotic effects in MTC cells. Therefore, Notch-1 activation with SBHA is an attractive new strategy for the treatment of patients with MTC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305053     DOI: 10.1634/theoncologist.2007-0190

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  28 in total

1.  A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Authors:  Tabraiz A Mohammed; Kyle D Holen; Renata Jaskula-Sztul; Daniel Mulkerin; Sam J Lubner; William R Schelman; Jens Eickhoff; Herbert Chen; Noelle K Loconte
Journal:  Oncologist       Date:  2011-05-31

2.  Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.

Authors:  Scott N Pinchot; Renata Jaskula-Sztul; Li Ning; Noel R Peters; Mackenzie R Cook; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

Authors:  Matthew Truong; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2010-12-24       Impact factor: 5.344

Review 4.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

5.  Concomitant endometrial and pancreatic cancers.

Authors:  S Michelle Shiller; Shawna L Bull Phelps; Jeffrey P Lamont; Granger R Scruggs
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

6.  Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.

Authors:  Li Ning; Renata Jaskula-Sztul; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-06-18       Impact factor: 5.344

7.  Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma.

Authors:  Li Ning; Lucy Wentworth; Herbert Chen; Sharon M Weber
Journal:  Am J Transl Res       Date:  2009-07-10       Impact factor: 4.060

8.  Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma.

Authors:  Max A Cayo; Ashley K Cayo; Sarah M Jarjour; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-01-31       Impact factor: 4.060

9.  Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway.

Authors:  Li Ning; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

10.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.